Similarly, it has been shown that inhibiting SRSF9 can enhance the sensitivity of CRC to ferroptosis, suggesting its probability as a potential therapeutic target (Wang X. et al., 2022). This evidence concerns the gene SRSF9 and colorectal carcinoma.